NLSPW

NLSPW

USD

NLS Pharmaceutics Ltd. Warrant

$0.018+0.002 (10.494%)

Reaalajas hind

Healthcare
Biotehnoloogia
Šveits

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$0.016

Kõrge

$0.021

Madal

$0.017

Maht

0.13M

Ettevõtte fundamentaalnäitajad

Tööstusharu

Biotehnoloogia

Riik

Switzerland

Kauplemisstatistika

Keskmine maht

0.04M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.001Praegune $0.018Kõrge $0.07

Seotud uudised

PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and...

Vaata rohkem
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger
PR Newswire

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

Vaata rohkem
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
PR Newswire

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

Vaata rohkem
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
PR Newswire

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that,...

Vaata rohkem
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
PR Newswire

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...

Vaata rohkem
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025